CVR number 31609135
Industry 477420

SVANEKLINIK ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  4.2% 3.4% 3.8% 4.9% 3.4%  
Credit score (0-100)  48 52 50 43 54  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  2,620 2,960 2,746 2,893 3,015  
EBITDA  590 824 320 191 815  
EBIT  586 817 320 191 815  
Pre-tax profit (PTP)  595.5 834.8 334.7 199.4 836.8  
Net earnings  460.9 647.1 257.2 151.8 646.7  
Pre-tax profit without non-rec. items  595 835 335 199 837  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  7.8 0.0 0.0 0.0 0.0  
Shareholders equity total  1,369 1,516 1,123 1,025 1,572  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.8  
Balance sheet total (assets)  2,652 2,475 1,817 1,921 2,454  
Net Debt  -752 -548 -412 -324 -806  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  2,620 2,960 2,746 2,893 3,015  
Gross profit growth  -13.4% 13.0% -7.2% 5.4% 4.2%  
Employees  4 4 4 5 6  
Employee growth %  0.0% 0.0% 0.0% 25.0% 20.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,652 2,475 1,817 1,921 2,454  
Balance sheet change%  15.9% -6.7% -26.6% 5.7% 27.8%  
Added value  590.4 824.5 319.7 191.4 815.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -8 -16 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  22.4% 27.6% 11.6% 6.6% 27.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  24.3% 32.8% 15.8% 10.9% 38.8%  
ROI %  43.2% 58.3% 25.8% 18.9% 65.3%  
ROE %  33.2% 44.9% 19.5% 14.1% 49.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  51.6% 61.3% 61.8% 53.4% 64.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -127.4% -66.4% -128.9% -169.5% -98.9%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.1%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 2,712.5%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.6 1.9 1.5 1.3 1.9  
Current Ratio  2.0 2.5 2.6 2.1 2.7  
Cash and cash equivalent  752.4 547.8 411.9 324.4 807.3  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,323.3 1,477.6 1,084.0 980.9 1,525.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  148 206 80 38 136  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  148 206 80 38 136  
EBIT / employee  147 204 80 38 136  
Net earnings / employee  115 162 64 30 108